Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label non-inferiority study of acalabrutinib versus ibrutinib in previously treated high-risk chronic lymphocytic leukemia
MOH_2017-03-20_000257Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing ACP-196 with Ibrutinib (2 arms). Started Jul 2015; status: active, not recruiting.
02
Drugs
acalabrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-03-20_000257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-20_000257.